Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St futures gain as AI enthusiasm eases worries over higher oil prices, yields
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil gains on little sign of progress in US-Iran talks
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Roth Positive on Ligand Pharma (LGND) Amid Another Key OmniAb Collaboration (GILD)
July 8, 2016 9:47 AM EDTRoth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) with a Buy rating and $147 price target following news of a new collaboration with Giled (Nasdaq: GILD).
Analyst Joseph Pantginis offered the following commentary on Friday: This new OmniAb agreement is part of... More
